PRNAF Alterity Therapeutics Ltd (PK)

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2023

 

Alterity Therapeutics Limited

(Name of Registrant)

 

Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  ☒       Form 40-F  ☐

 

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

 

 

 

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

 

The following exhibits are submitted:

 

99.1

Proposed issue of securities - ATH

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Alterity Therapeutics Limited
	By:	/s/ Geoffrey P. Kempler
		Geoffrey P. Kempler
		Chairman

 

Date: November 22, 2023

  

 

2

 

Exhibit 99.1

 

Proposed issue of securities

 

 

Announcement Summary

 

Entity name

ALTERITY THERAPEUTICS LIMITED

 

Announcement Type

New announcement

 

Date of this announcement

22/11/2023

 

The Proposed issue is:

þ A placement or other type of issue

 

Total number of +securities proposed to be issued for a placement or other type of issue

 

ASX+security code	+Security description	Maximum Number of +securities to be issued
New class-code to be confirmed	Short-dated option	1,371,428,571
New class-code to be confirmed	Long-dated options	457,142,857
ATH	ORDINARY FULLY PAID	1,008,965,809

 

Proposed +issue date

12/1/2024

 

Refer to next page for full details of the announcement

 

 

Proposed issue of securities

 

Part 1 - Entity and announcement details

 

1.1 Name of +Entity

ALTERITY THERAPEUTICS LIMITED

 

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

 

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

 

1.2 Registered Number Type	Registration Number
ABN	37080699065

 

1.3 ASX issuer code

ATH

 

1.4 The announcement is

þ New announcement

 

1.5 Date of this announcement

22/11/2023

 

1.6 The Proposed issue is:

þ A placement or other type of issue

 

 

Proposed issue of securities

 

Part 7 - Details of proposed placement or other issue

 

Part 7A - Conditions

 

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

þ Yes

 

7A.1a Conditions

 

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	29/12/2023	þ Estimated

 

Comments

 

Part 7B - Issue details

 

Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)?	Will the proposed issue of this +security include an offer of attaching +securities? þ Yes
þ Existing class

 

Details of +securities proposed to be issued

 

ASX +security code and description

ATH : ORDINARY FULLY PAID

 

Number of +securities proposed to be issued

1,008,965,809

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

þ Yes

 

 

Proposed issue of securities

 

In what currency is the cash consideration being paid?	What is the issue price per +security?
AUD - Australian Dollar	AUD 0.00350

 

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

þ Yes

 

Attaching +Security

 

Is the proposed attaching security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional +securities in a class that is already quoted or recorded by ASX)?

þ New class

 

Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX)

 

Details of attaching +securities proposed to be issued

 

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

 

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?	Will the entity be seeking quotation of the ‘new’ class of +securities on ASX? þ No
þ No
ASX +security code	+Security description
New class-code to be confirmed	Short-dated option

 

+Security type

Options

 

Number of +securities proposed to be issued

1,371,428,571

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

þ No

 

Please describe the consideration being provided for the +securities

One (1) free attaching short-dated option issued for each Placement share issued per Placement announcement 22 Nov 2023

 

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

 

 

Proposed issue of securities

 

Will all the +securities issued in this class rank equally in all respects from their issue date?

þYes

 

Options details

 

+Security currency

AUD - Australian Dollar

 

Exercise price	Expiry date
AUD 0.0070	31/8/2024

 

Details of the type of +security that will be issued if the option is exercised

ATH : ORDINARY FULLY PAID

 

Number of securities that will be issued if the option is exercised

One ATH fully paid ordinary share

 

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://alteritytherapeutics.com/investor-overview/asx-announcements/

 

Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)?	Will the proposed issue of this +security include an offer of attaching +securities? þ No
þ New class

 

Details of +securities proposed to be issued

 

ISIN Code (if Issuer is a foreign company and +securities are non CDIs)

 

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?	Will the entity be seeking quotation of the ‘new’ class of +securities on ASX?
þ No	þ Yes
ASX +security code	+Security description
New class-code to be confirmed	Long-dated options

 

+Security type

Options

 

 

Proposed issue of securities

 

Number of +securities proposed to be issued

457,142,857

 

Offer price details

 

Are the +securities proposed to be issued being issued for a cash consideration?

þ No

 

Please describe the consideration being provided for the +securities

One (1) free attaching long-dated option issued for each three (3) Placement share issued per Placement announcement 22 Nov 2023

 

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities

 

Will all the +securities issued in this class rank equally in all respects from their issue date?

þ Yes

 

Options details

 

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.0100	31/8/2026

 

Details of the type of +security that will be issued if the option is exercised

ATH : ORDINARY FULLY PAID

 

Number of securities that will be issued if the option is exercised

One ATH fully paid ordinary share

 

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

https://alteritytherapeutics.com/investor-overview/asx-announcements/

 

Part 7C - Timetable

  

7C.1

Proposed +issue date

12/1/2024

 

 

Proposed issue of securities

 

Part 7D - Listing Rule requirements

 

7D.1

Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

þ

Yes

 

7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1

29/12/2023

 

7D.2

Is a party referred to in listing rule 10.11 participating in the proposed issue?

þ

Yes

 

7D.3

Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

þ

No

 

7D.4

Will any of the +securities to be issued be subject to +voluntary escrow?

þ

No

 

Part 7E - Fees and expenses

 

7E.1 Will there be a lead manager or broker to the proposed issue?

þ

Yes

 

7E.1a Who is the lead manager/broker?

MST Financial Services Pty Ltd

 

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

6% of amount raised under Placement

 

7E.2 Is the proposed issue to be underwritten?

þ

No

 

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

 

Part 7F - Further Information

 

7F.01 The purpose(s) for which the entity is issuing the securities

The use of proceeds from this financing will provide ongoing funding of Alterity’s Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital.

 

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? 

þ

No

 

7F.2 Any other information the entity wishes to provide about the proposed issue

 

7F.3

Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

þ

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

 

---